论文部分内容阅读
目的探讨布地奈德雾化吸入治疗慢性阻塞性肺疾病(COPD)急性加重期临床疗效及应用价值。方法将2010年3月-2011年4月我院收治的COPD急性加重期108例患者分成治疗组和对照组,对照组给予单一沙丁醇雾化吸入治疗,治疗组在此基础上再给与布地奈德雾化吸入治疗,观察两组临床疗效和肺部、血气指标变化情况,并进行对比分析。结果治疗组总有效率为96.30%,明显高于对照组的79.63%(P<0.05);两组患者治疗后各血气指标均较治疗前有明显改善,组内(治疗前后)比较有显著性差异(P<0.05);治疗组治疗后各血气指标均优于对照组,组间比较有显著差异(P<0.05)。结论采用布地奈德雾化吸入治疗COPD急性加重期患者临床疗效显著,值得推广使用。
Objective To investigate the clinical efficacy and the clinical value of inhaled budesonide in the treatment of acute exacerbation of chronic obstructive pulmonary disease (COPD). Methods From March 2010 to April 2011, 108 cases of acute exacerbation of COPD admitted to our hospital were divided into treatment group and control group. The control group received single inhalation of sardinol inhalation. The treatment group was given on the basis of this Budesonide inhalation therapy, observation of the two groups of clinical efficacy and changes in lung, blood gas indicators, and comparative analysis. Results The total effective rate of the treatment group was 96.30%, which was significantly higher than that of the control group (79.63%, P <0.05). The blood gas indexes of the two groups were significantly improved after treatment compared with those before treatment, and there was significant difference between before and after treatment (P <0.05). The blood gas indexes of the treatment group were better than those of the control group after treatment, there were significant differences between the two groups (P <0.05). Conclusions The use of budesonide inhalation in the treatment of acute exacerbation of COPD patients with significant clinical efficacy, it is worth promoting the use of.